{
  "abstract": "Febuxostat is a non-purine xanthine oxidase inhibitor primarily used to treat gout and hyperuricaemia. Although it has a better safety profile compared to allopurinol, febuxostat has been associated with rare cases of drug-induced liver injury. We present a case of a man in his late 50s who developed liver injury after switching from allopurinol to febuxostat for gout management. The patient experienced fatigue, nausea, jaundice and had notably elevated aminotransferase activities. A liver biopsy revealed moderate acute hepatocellular injury. After discontinuing febuxostat, the liver tests did not improve for 1 month until treatment with prednisone. This case adds to the existing literature on febuxostat-induced liver injury and highlights the variability in clinical and histological manifestations. It also emphasises the importance of monitoring liver tests in patients taking febuxostat.",
  "authors": [
    {
      "affiliations": [
        "Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA",
        "Gastroenterology/Hepatology, UCSF, San Francisco, California, USA"
      ],
      "name": "Joanne Lin"
    },
    {
      "affiliations": [
        "Pathology, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA"
      ],
      "name": "David Braxton"
    },
    {
      "affiliations": [
        "Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA"
      ],
      "name": "Tse-Ling Fong"
    }
  ],
  "title": "Febuxostat-induced hepatocellular injury",
  "uid": "c245ef2a-282f-5418-a76e-b3f8ea4a076c"
}